chevron_leftBack
As of 14 June 2026, Walvax Biotechnology Co., Ltd. has a market cap of $3.04B USD, ranking #5374 globally and #1153 in China.
It ranks #417 in the Healthcare sector, and #75 in the Biotechnology industry.
Key Stats
Market Cap
$3.04BUSD
20.62B CNY
Enterprise Value
$3.12BUSD
21.1B CNY
Revenue (TTM)
$354.17MUSD
2.4B CNY
EBITDA (TTM)
$92.5MUSD
625.96M CNY
Net Income (TTM)
$42.17MUSD
285.77M CNY
EBITDA Margin
26%
Profit Margin
12%
PE Ratio
72.6
Forward PE
70.6
PS Ratio
8.6
PB Ratio
2.6
EV/EBITDA
33.1
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Biotechnology
CEO
Wei Yao
open_in_new
Employees
1,981
Founded
2001
Website
walvax.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| 0.9% | 5% | 6.9% | -1.2% | 14% | 29% |
News
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
300142
云南沃森生物技术股份有限公司 Class A
ISIN: CNE100000WN2
Shares Out.:
Shares Outstanding:
1.559B1
Shares Float:
1.196B2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
13.00 CNY |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Walvax Biotechnology Co., Ltd.
Walvax Biotechnology Co., Ltd., engages in the research and development, manufacture, and distribution of vaccines in China and internationally. Its vaccine portfolio includes recombinant human papillomavirus bivalent, 13-valent pneumococcal polysaccharide conjugate, 23-valent pneumococcal polysaccharide, group ACYW135 meningococcal polysaccharide, group A and C meningococcal polysaccharide, group A and group C meningococcal conjugate, and haemophilus influenzae type b conjugate vaccines, as well as diphtheria, tetanus and acellular pertussis combined vaccine. The company was founded in 2001 and is headquartered in Kunming, China.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
SHEK: 2269
|
$17.44B
473%
136.71B HKD
|
25.3
|
|
SHEK: 1093
|
$12.2B
301%
95.58B HKD
|
22.1
|
|
SHE: 002422
|
$8.0B
163%
54.23B CNY
|
34.4
|
|
|
$7.33B
141%
49.69B CNY
|
-
|
||
SHEK: 1530
|
$7.08B
133%
55.5B HKD
|
5.8
|
|
SHE: 300347
|
$6.72B
121%
45.52B CNY
|
61.6
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NASDAQ: AMGN
|
$182.42B
6K%
|
23.9
|
|
NASDAQ: GILD
|
$159.92B
5K%
|
19.0
|
|
EBR: ARGX
|
$47.84B
1K%
41.39B EUR
|
39.9
|
|
KRX: 207940
|
$44.84B
1K%
68.19T KRW
|
35.5
|
|
ASX: CSL
|
$42.36B
1K%
60.27B AUD
|
29.3
|
|
SIX: LONN
|
$42.3B
1K%
33.71B CHF
|
37.2
|
chevron_leftBack